Home > Oncology > ASCO 2022 > Novel treatment option for KRAS wild-type pancreatic cancer

Novel treatment option for KRAS wild-type pancreatic cancer

Presented By
Prof. Thomas Seufferlein, Ulm University Hospital, Germany
ASCO 2022
Phase 3, NOTABLE
Gemcitabine plus nimotuzumab demonstrated overall survival (OS) benefits over gemcitabine alone for patients with KRAS wild-type metastatic pancreatic ductal adenocarcinoma (mPDAC) or locally advanced pancreatic cancer (LAPC). The results of the phase 3 Notable trial show the value of determining KRAS status in pancreatic cancer. Activation of the epidermal growth factor receptor (EGFR)-Ras-Raf-MEK-ERK pathway plays a part in patients with KRAS wild-type pancreatic cancer [1]. Therefore, the phase 3 Notable trial (NCT02395016) randomised patients with KRAS wild-type locally advanced or metastatic pancreatic cancer to gemcitabine and placebo (n=41) or gemcitabine plus nimotuzumab (n=41), which is an EGFR-targeting monoclonal antibody [2,3]. OS was the primary endpoint of this study. Prof. Thomas Seufferlein (Ulm University Hospital, Germany) present...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on